Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 459 across all filing types
Latest filing 2023-12-20 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ocumension Therapeutics. It details repurchases of shares on specific dates, quantities, prices, and confirms compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on share repurchase activities and disclosures required by the exchange rules. There are no financial statements, earnings data, or management discussion. The document is a regulatory disclosure about share repurchases, fitting the category of Transaction in Own Shares (POS). The document length and detail confirm it is not a brief announcement but a formal disclosure report on share repurchases.
2023-12-20 English
VOLUNTARY ANNOUNCEMENT APPROVAL RECEIVED FOR MARKETING OT-703 IN HONG KONG
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the approval received for marketing a pharmaceutical product (OT-703) in Hong Kong. It is an update on business developments and regulatory approval, not a financial report or detailed filing. The document is relatively short (3374 characters) and serves as a business update rather than a formal report or regulatory filing. It does not contain financial statements, audit information, or detailed management discussion. It is not an announcement of voting results, board changes, or capital changes. Therefore, it fits best under the category of a general regulatory announcement or business update, which aligns with Regulatory Filings (RNS).
2023-12-20 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ocumension Therapeutics. It includes detailed data on repurchases of shares, dates, prices, and confirmations that these repurchases comply with listing rules. The document is a regulatory disclosure about share repurchases and capital changes, not a full financial report or earnings release. It is not an announcement of a report publication but a substantive disclosure of share capital changes. This fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares.
2023-12-19 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ocumension Therapeutics, a listed issuer on the Stock Exchange of Hong Kong. It details repurchases of shares, dates, quantities, prices, and confirmations that these repurchases comply with listing rules. The document is a regulatory disclosure about share repurchases and changes in capital, not a full financial report or earnings release. It is not an announcement of a report publication but a formal regulatory filing required by the exchange. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares.
2023-12-18 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ocumension Therapeutics. It details repurchases of shares, dates, prices, and confirmations that these repurchases comply with listing rules. The document is a regulatory disclosure about share repurchases and changes in capital, not a full financial report or earnings release. It fits the description of a Transaction in Own Shares (POS) filing, which reports company buybacks or sales of its own shares. The document length and content confirm it is not a brief announcement but a detailed disclosure of share repurchase activity.
2023-12-15 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is a Next Day Disclosure Return related to changes in issued share capital and share buybacks by Ocumension Therapeutics, a listed issuer on the Stock Exchange of Hong Kong. It details repurchases of shares, including dates, quantities, prices, and confirmations of compliance with listing rules. The document is regulatory in nature, reporting share repurchase activity and capital changes, but it is not a full financial report, earnings release, or management discussion. It is a formal regulatory filing disclosing share capital changes and repurchases as required by the exchange rules. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length and detail confirm it is not a brief announcement but a substantive disclosure report.
2023-12-14 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.